BRAF and neoplasm: Furthermore, abemaciclib yielded tumor growth regression in a vemurafenib-resistant model, and induced apoptotic cell death in a concentration-dependent manner, suggesting that this drug might be a viable therapeutic option to overcome MAPK-mediated resistance to B-RAF inhibitors in B-RAF V600E melanoma (55).